Analyzing Minerva Surgical (NASDAQ:UTRS) and Perspective Therapeutics (NYSE:CATX)

Minerva Surgical (NASDAQ:UTRS) and Perspective Therapeutics (NYSE:CATX) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, profitability, valuation, analyst recommendations, institutional ownership, earnings and risk.

Analyst Recommendations

This is a breakdown of current recommendations for Minerva Surgical and Perspective Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Minerva Surgical	0	0	0	0	0.00
Perspective Therapeutics	0	1	8	0	2.89

Perspective Therapeutics has a consensus price target of $15.14, suggesting a potential upside of 431.33%. Given Perspective Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Perspective Therapeutics is more favorable than Minerva Surgical.

Profitability

This table compares Minerva Surgical and Perspective Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Minerva Surgical	N/A	N/A	N/A
Perspective Therapeutics	-4,096.66%	-27.40%	-23.16%

Earnings & Valuation

This table compares Minerva Surgical and Perspective Therapeutics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Minerva Surgical	$51.69 million	0.00	-$34.11 million	($8.21)	N/A
Perspective Therapeutics	$1.43 million	134.70	-$46.51 million	N/A	N/A

Minerva Surgical has higher revenue and earnings than Perspective Therapeutics.

Institutional & Insider Ownership

54.7% of Perspective Therapeutics shares are owned by institutional investors. 8.5% of Minerva Surgical shares are owned by company insiders. Comparatively, 3.5% of Perspective Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Risk and Volatility

Minerva Surgical has a beta of 3.96, indicating that its share price is 296% more volatile than the S&P 500. Comparatively, Perspective Therapeutics has a beta of 1.13, indicating that its share price is 13% more volatile than the S&P 500.

Summary

Minerva Surgical beats Perspective Therapeutics on 7 of the 11 factors compared between the two stocks.

About Minerva Surgical

Minerva Surgical, Inc., a commercial-stage medical technology company, develops, manufactures, and commercializes minimally invasive solutions to meet the uterine healthcare needs of women in the United States. The company provides Minerva ES Endometrial Ablation System and Genesys HTA Endometrial Ablation System, which are endometrial ablation devices; Symphion Tissue Removal System, a minimally invasive uterine tissue removal system to combine bladeless tissue resection and coagulation, continuous visualization, and intrauterine pressure monitoring; and Resectr Tissue Resection Device, a handheld surgical instrument to enable the hysteroscopic removal and diagnosis of endometrial polyps. Its devices are utilized by obstetrician-gynecologists in various medical treatment settings, including hospitals, ambulatory surgical centers, and physician offices. The company was incorporated in 2008 and is headquartered in Santa Clara, California.

About Perspective Therapeutics

Perspective Therapeutics, Inc., together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma. Perspective Therapeutics, Inc. has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is headquartered in Seattle, Washington.